Scientists unlock rare cannabis compound with powerful anti-inflammatory effects

This research presents a breakthrough in producing cannabistilbene I, a rare anti-inflammatory compound found in cannabis, using a cell-free biocatalytic synthesis method. Rather than trying to extract this compound directly from plants or create it through traditional chemical synthesis, researchers identified two key enzymes—a Cannabis O-methyltransferase (CsOMT1) and a prenyltransferase from bacteria—that work together to synthesize cannabistilbene I in a laboratory setting. The study provides detailed structural insights into how these enzymes function, revealing that CsOMT1's active site requires precise molecular geometry to process its substrate effectively.

What makes this compound particularly valuable is its dual anti-inflammatory mechanism: cannabistilbene I was shown to inhibit both microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase, two key enzymes involved in inflammation pathways. Remarkably, the compound demonstrated greater potency than leading commercial inhibitors of these enzymes in laboratory testing. This is significant because blocking both pathways simultaneously could provide more comprehensive anti-inflammatory effects than single-pathway drugs.

The broader impact of this research extends beyond just one compound. By establishing this biocatalytic production platform, scientists have created a scalable method to produce cannabistilbene I and similar rare cannabis-derived compounds that are difficult to obtain from traditional sources. This approach overcomes the challenge of natural scarcity—cannabistilbene I and related bibenzyls are present in cannabis plants in very low concentrations, making them impractical to harvest. The cell-free synthesis method is more efficient, sustainable, and could accelerate the development of cannabis-based therapeutic options for inflammatory conditions.